Anemia | CHOP Research Institute

Phase 3 Beta Thalassemia LentiGlobin BB305 Gene Therapy Trial

Individuals with certain types of beta thalassemia that is treated with regular transfusions and who are up to 50 years old may be able to participate. A number of screening tests will be done to determine if subjects can participate.

Comprehensive Center for the Cure of Sickle Cell Disease and Other Red Blood Cell Disorders

Pioneering new approaches to diagnosis, care, and treatment for patients with red blood cell disorders with novel gene therapies and stem-cell-based treatments that aim to reduce symptoms and prolong life.

Stella T. Chou, MD

Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.

E-mail:

chous [at] chop.edu

Elizabeth Lowenthal, MD, MSCE

Dr. Lowenthal's work is focused on addressing health priorities for children in resource-limited settings. In addition to research projects she serves as research director for the Children's Hospital of Philadelphia Global Health Center, supporting junior researchers (and senior researchers newly working in international settings) to develop projects addressing other health priorities for children in resource-limited settings.

E-mail:

lowenthale [at] chop.edu

International Team Finds Blood Disorder Mutation

Published on

Nov 26, 2014

in Cornerstone Blog

An international team of gene experts has identified a mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells.

Treating the Chicken with the Egg

Published on

Jan 28, 2014

in Cornerstone Blog

The term “stem cell,” stammzellen, was first used in 1868 by the German biologist Ernst Haeckel to describe the original, unicellular progenitor from which Dr. Haekel supposed all multicellular plant and animal life might have descended.